TY - JOUR
T1 - Concentration of hs-Troponin in small cohort of transgender patients
AU - Boone, Stephen
AU - Peacock, W. Frank
AU - Wu, Alan H.B.
AU - Jaffe, Allan
AU - Christenson, Robert H.
AU - Ettner, Frederic M.
AU - Dadkhah, Shahriar
N1 - Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2023/1/15
Y1 - 2023/1/15
N2 - Introduction: Sex-differences in high sensitivity troponin (hs-Tn) concentrations are well established. There is, however, limited data to guide interpretation of hs-Tn in transgender patients, particularly those receiving gender-affirming hormone therapy. Our purpose was to evaluate troponin testing in transgender patients. Methods: Transgender adults attending a routine clinic visit provided demographic data, medical history, and venous blood samples. Patients with congestive heart failure or chronic kidney disease were excluded. hs-Tn was measured using the Architect Stat High Sensitivity Troponin-I (Abbott), Access 2 hsTnI (Beckman Coulter), and Elecsys Troponin T Gen 5 STAT (Roche) assays. hs-Tn below the limit of detection (LOD) is reported as the lower limit of detection (LLOD) Results: Of 63 subjects, 76 % were transgender women. We found no significant difference in median hs-Tn concentrations or proportions of hs-Tn > LOD. Conclusion: In this cohort of stable transgender patients without CHF or CKD, we did not observe differences in hs-Tn concentrations between transgender women and transgender men. Meaningful conclusions are limited owing to inadequate sample size and population differences. Further research on hs-troponin concentrations in this underrepresented, vulnerable population is needed.
AB - Introduction: Sex-differences in high sensitivity troponin (hs-Tn) concentrations are well established. There is, however, limited data to guide interpretation of hs-Tn in transgender patients, particularly those receiving gender-affirming hormone therapy. Our purpose was to evaluate troponin testing in transgender patients. Methods: Transgender adults attending a routine clinic visit provided demographic data, medical history, and venous blood samples. Patients with congestive heart failure or chronic kidney disease were excluded. hs-Tn was measured using the Architect Stat High Sensitivity Troponin-I (Abbott), Access 2 hsTnI (Beckman Coulter), and Elecsys Troponin T Gen 5 STAT (Roche) assays. hs-Tn below the limit of detection (LOD) is reported as the lower limit of detection (LLOD) Results: Of 63 subjects, 76 % were transgender women. We found no significant difference in median hs-Tn concentrations or proportions of hs-Tn > LOD. Conclusion: In this cohort of stable transgender patients without CHF or CKD, we did not observe differences in hs-Tn concentrations between transgender women and transgender men. Meaningful conclusions are limited owing to inadequate sample size and population differences. Further research on hs-troponin concentrations in this underrepresented, vulnerable population is needed.
KW - Cardiac biomarkers
KW - High-sensitivity troponin
KW - Transgender
KW - Troponin
UR - http://www.scopus.com/inward/record.url?scp=85143674848&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143674848&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2022.12.003
DO - 10.1016/j.cca.2022.12.003
M3 - Article
C2 - 36495928
AN - SCOPUS:85143674848
SN - 0009-8981
VL - 539
SP - 66
EP - 69
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
ER -